Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
366.54
513.76
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
112.5B USD |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
Market Distribution
| Min | -1 924 693.3% |
| 30th Percentile | 3.4% |
| Median | 10% |
| 70th Percentile | 17.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Vertex Pharmaceuticals Inc
Glance View
In the bustling landscape of biotechnology, Vertex Pharmaceuticals Inc. stands out as a dynamic powerhouse that has deftly carved a niche in the complex domain of genetic therapies. Founded in 1989, the company initially embarked on a mission to revolutionize drug discovery through a cutting-edge rational drug design approach. Armed with an innovative spirit and a focus on niche markets, Vertex turned its attention towards cystic fibrosis—a life-shortening genetic disorder affecting the lungs and digestive system. The company’s breakthrough came with the development and approval of the first therapies that address the underlying cause of cystic fibrosis, rather than just alleviating symptoms. These products, including Kalydeco and Trikafta, have repositioned Vertex from a scrappy biotech upstart to a dominating force in the drug market as these life-changing treatments not only improve patient outcomes but also command premium pricing. Vertex’s business model brilliantly capitalizes on its deep investment in research and development, allowing it to maintain a robust pipeline that promises ongoing growth. By channeling a substantial portion of its revenue back into R&D, Vertex seeks to extend its therapeutic successes beyond cystic fibrosis into other serious diseases with high unmet needs, such as sickle cell disease and beta-thalassemia. This strategic reinvestment supports a cyclical framework of innovation—capitalize on current successes while laying down the groundwork for future therapies. With a singular focus on specialty drugs that target specific genetic mutations or pathways, Vertex not only thrives on the immediate financial returns of its blockbuster drugs but continually invests in scientifically ambitious endeavors, thus reinforcing its status as a leader in the precision medicine sector.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Vertex Pharmaceuticals Inc is 38.7%, which is below its 3-year median of 43%.
Over the last 3 years, Vertex Pharmaceuticals Inc’s Operating Margin has decreased from 48.9% to 38.7%. During this period, it reached a low of 37.9% on Mar 31, 2025 and a high of 49.7% on Dec 31, 2022.